上海醫藥(02607.HK)前三季度淨利潤增長0.8%至33.99億元
格隆匯10月30日丨上海醫藥(02607.HK)發佈2019年三季度報告,今年前三季度,公司實現營業收入1.41億元(人民幣,下同),同比增長19.57%;歸屬於上市公司股東的淨利潤33.99億元,同比增長0.80%;基本每股收益1.1959元。
公告表示,1-9月公司主營業務持續較快增長,實現營業收入1,406.17億元,同比增長19.57%;其中醫藥工業實現收入176.82億元,同比增長24.05%;醫藥商業實現收入1,229.35億元,同比增長18.95%。公司實現歸屬於上市公司股東的淨利潤33.99億元,同比增長0.80%,實現扣除非經常性損益的歸屬於上市公司股東淨利潤30.70億,同比增長19.62%。醫藥工業主營業務貢獻利潤15.40億元,同比增長20.56%;醫藥商業主營業務貢獻利潤15.26億元,同比增長15.73%;參股企業貢獻利潤8.04億元,同比增長48.13%。
此外,1-9月公司綜合毛利率13.70%,較上年同期下降0.11個百分點;扣除管理、銷售及研發費用後的營業利潤率3.79%,較上年同期下降0.14個百分點。公司繼續保持良好的運營質量,報告期內經營性現金流淨流入29.32億元,同比增長69.19%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.